ENXTAM:GLPGBiotechs
Why Galapagos (ENXTAM:GLPG) Is Down 7.9% After Exiting Cell Therapy and Cutting 365 Jobs
Galapagos NV announced its intention to wind down its cell therapy business, following a comprehensive strategic review and unsuccessful divestiture attempts, affecting approximately 365 employees and leading to site closures in Europe, the U.S., and China.
This significant shift highlights the company's plan to redirect available cash towards building a pipeline of novel therapeutics through targeted business development, under recently refreshed leadership.
We’ll examine how the decision...